The small molecule LOXL2 inhibitor SNT-5382 reduces cardiac fibrosis and achieves strong clinical target engagement by Lara Perryman, Alison Findlay, Jana Baskar, Brett Charlton, Jonathan Foot, Ross Hamilton, Dieter Hamprecht, Amar Joshi, Jessica Stolp, Craig Turner, Amna Zahoor, Wenbin Zhou, Begoña López, Susana Ravassa, Arantxa González, Wolfgang Jarolimek

Get full text